INSM earnings call for the period ending December 31, 2018.
News & Analysis: Insmed
These biotech stocks jumped 31% or more over the last few days. Can their momentum continue?
These companies arguably stole the show at J.P. Morgan's high-profile healthcare conference this year.
Investors are impressed with early sales numbers for the biotech's Arikayce antibiotic.
The FDA gave its new drug a thumbs-up. So why are share prices down?
Insmed, Newlink Genetics, and Voyager Therapeutics stocks soar on positive news.
Investment-bank analysts pinned price targets to these two biotechs that are more than double their recent prices. Here's what you need to know.
These stocks more than held their own despite a drop in the broader market. Find out why.
Shares more than doubled after the company announced top-line results from an important phase 3 clinical trial.
Two pharma giants walk away from collaborations, another investigational drug receives the breakthrough designation, and more M&A activity are this week's biggest biotech stories.